The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of elacytarabine plus idarubicin as second course remission-induction therapy in patients with acute myeloid leukemia.
D. Rizzieri
No relevant relationships to disclose
U. Krug
No relevant relationships to disclose
R. F. Schlenk
No relevant relationships to disclose
N. Vey
No relevant relationships to disclose
X. G. Thomas
No relevant relationships to disclose
F. Huguet
No relevant relationships to disclose
M. Johansen
Employment or Leadership Position - Clavis Pharma
Honoraria - Clavis Pharma
Research Funding - Clavis Pharma
T. F. Jacobsen
Employment or Leadership Position - Clavis Pharma
Stock Ownership - Clavis Pharma
Honoraria - Clavis Pharma
Research Funding - Clavis Pharma